Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)

NCT01822652 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01822652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 31, 2013
Completion date
October 31, 2030
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma